Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesvategrast in Diabetic Retinopathy (DR:EAM)
NCT05409235Phase 2Completed
- Sponsor
- OcuTerra Therapeutics
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of nesvategrast in diabetic retinopathy (DR), sponsored by OcuTerra Therapeutics. Started Jul 2022; status: completed.
02
Drugs
nesvategrast
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05409235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409235.